Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Endeavor BioMedicines

Endeavor BioMedicines Appoints Internationally Renowned ILD Expert Lisa Lancaster, M.D., as Chief Medical Officer
From Endeavor BioMedicines
Via Business Wire
First Patient Dosed in Endeavor BioMedicines’ Phase 2b WHISTLE-PF Trial Evaluating ENV-101 for the Treatment of Idiopathic Pulmonary Fibrosis
From Endeavor BioMedicines
Via Business Wire
Endeavor BioMedicines Appoints Bill Bradford, M.D., Ph.D., to Board of Directors
From Endeavor BioMedicines
Via Business Wire
New Phase 2a Clinical Trial Results Demonstrate Endeavor BioMedicines’ ENV-101 Improved Lung Function and Reversed Key Measures of Lung Fibrosis in Patients With Idiopathic Pulmonary Fibrosis
From Endeavor BioMedicines
Via Business Wire
Endeavor BioMedicines to Present New Data From Phase 2a Clinical Trial of ENV-101 at American Thoracic Society 2024 International Conference
From Endeavor BioMedicines
Via Business Wire
Endeavor BioMedicines Announces Appointment of Chris Krueger, J.D., as Chief Operating Officer
From Endeavor BioMedicines
Via Business Wire
Endeavor BioMedicines Appoints Enoch Kariuki, Pharm.D. as President and Vishaal Turakhia as Chief Financial Officer
From Endeavor BioMedicines
Via Business Wire
Endeavor BioMedicines Successfully Completes Phase 2a Trial of ENV-101 in Patients with Idiopathic Pulmonary Fibrosis
From Endeavor BioMedicines
Via Business Wire
Endeavor BioMedicines Appoints Enoch Kariuki, Pharm.D. to Board of Directors
From Endeavor BioMedicines
Via Business Wire
Endeavor BioMedicines Appoints Paul Frohna, M.D., Ph.D., as Chief Medical Officer
From Endeavor BioMedicines
Via Business Wire
Endeavor BioMedicines Completes Enrollment in Phase 2a Clinical Trial of ENV-101 (Taladegib) for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)
From Endeavor BioMedicines
Via Business Wire
Endeavor BioMedicines Partners with xCures to Identify Patients with PTCH1 mutations for Phase 2 Trial of ENV-101 (taladegib)
From Endeavor BioMedicines
Via Business Wire
Endeavor Doses First Patient in Phase 2 Oncology Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib)
From Endeavor BioMedicines
Via Business Wire
Endeavor BioMedicines Closes $101M Series B Financing to Advance Clinical-Stage Precision Medicine Pipeline
From Endeavor BioMedicines
Via Business Wire
Endeavor BioMedicines Doses First Patient in Phase 2 Clinical Trial of Taladegib (ENV-101) for Idiopathic Pulmonary Fibrosis; Appoints Chief Medical Officer
From Endeavor BioMedicines
Via Business Wire
Endeavor BioMedicines Licenses ULK1/2 Inhibitor Program from Salk Institute and Sanford Burnham Prebys to Broaden Its Precision Oncology Pipeline
From Endeavor BioMedicines
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.